Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Comment by farmerjaneon Apr 10, 2015 5:18pm
191 Views
Post# 23618125

RE:AMF-Sedar-March 31, 2015

RE:AMF-Sedar-March 31, 2015Nrgzr, the information in the Annual Information Form, is for the most part old information posted in the past. If you search 2014's dated June 11, 2014, posted on Sedar Jun 27, 2014 you will see the same information even more twice the file. All they did for this latest one was add in a few lines here and there....you will even find that particular page you are asking about back in 2012. 

For the shares.....In Amorfix's management proxy dated Aug 25, 2014, it was stated that a total of 7,371,014 commons shares for Directors and Executive officers....Hans Black steped down 5 days before "retiring" August 20, 2014, so his numbers were not included. Included in this total is Cashman's 4,865,644 common shares. It was also noted that Interinvest had a total number of 10,713,222 common shares, in which Hans Black a former director is the Chairman of Interinvest.

The company had another PP on October 21, 2014 for 1,260,000 common shares in which Copeland recorded through insider trading taking 1,080,000 of those common shares...

Total shares reported  Aug 25,2014 (7,371,014 + 1,080,000 + 170,000) insider Buys= 8,621,014

Bullboard Posts